Mytocel MSKUnited Kingdom
The Mytocel MSK processing unit on a sterile drape, its branded side panel and device label in view

Autologous cartilage micrografting

Mytocel MSK. Prepared from the patient’s own cartilage, at the point of care.

Mytocel MSK® is an autologous cartilage micrografting procedure: the patient’s own auricular cartilage, mechanically disaggregated at the point of care into an injectable micrograft suspension.

Request UK pricingReview the evidence
Tissue source
Auricular cartilage, three 2.5 mm biopsies
Processing
Mechanical disaggregation, 80 µm
Laboratory step
None
Session
One outpatient visit, about 30 minutes
Devices
Rigeneracons® RS (Class IIa), N4SA (Class I)
UK supply
Actomed, exclusive

How it works

Four stages. One outpatient session.

Sampling, processing and administration in one outpatient session of around 30 minutes.

Explainer plate showing how the protocol works: prepare and anaesthetise the ear, take a tiny tissue sample, prepare the micrograft solution and inject it into the affected joint.
Illustrative representation of the protocol stages, from donor-site preparation to administration
  1. 01

    Prepare

    Establish the sterile field and prepare the posterior auricular donor area under local anaesthetic, following the current professional protocol.

  2. 02

    Sample

    Take three 2.5 mm punch biopsies from the posterior auricular cartilage using the documented technique. No sutures are required.

  3. 03

    Process

    Disaggregate the samples mechanically in Rigeneracons® RS on the N4SA processing unit and collect the AMT® suspension through the calibrated 80 µm filter. No laboratory step.

  4. 04

    Administer

    Administer the suspension to the target joint by intra-articular injection within the same session, then complete aftercare and follow-up arrangements.

See the full procedure
Cutaway of the single-use cartridge holding the patient’s cartilage sample, beside a key to the micrograft composition: progenitor cells, chondrocytes, pericytes, extracellular-matrix components and genetic material
The patient’s own tissue in the cartridge, and what the micrograft suspension contains. Manufacturer’s illustration

What the suspension contains

A suspension prepared from the patient’s own cartilage.

Characterisation studies describe a heterogeneous suspension of cartilage-derived cells (chondrocytes and progenitor cells), pericytes and extracellular-matrix components from the donor tissue.1

Mechanical disaggregation only: no laboratory expansion, no enzymatic digestion, no culture step.

Micrografts are collected through a calibrated 80 µm filter, the size range associated with viable progenitor-rich fractions in the characterisation work.1

Read about the technology

Evidence

Three-year follow-up. Two prospective series. Every study linked in full.

Nine publications and two preliminary reports: a three-year follow-up series (n = 8), two prospective ten-patient studies to 6 and 12 months, preliminary clinical reports, pre-clinical models and mechanistic characterisation. No randomised controlled trial has been published.234

n = 82

Three-year follow-up series in knee chondropathy

373

Patients across the four published knee series, all uncontrolled

450,000+5

Procedures with the technology worldwide, all fields, manufacturer-reported

Read the evidence

Indications

Documented for early to moderate cartilage disease.

Manufacturer-documented indications: knee osteoarthritis grade I to III (Kellgren-Lawrence), focal cartilage injury or damage, chondromalacia patellae.

Not indicated in grade IV

Not indicated where articular cartilage is absent (grade IV). The protocol requires that the joint preserves at least part of the articular cartilage.
Indications and patient selection
Gloved hands administering an injection into a patient’s knee.
Intra-articular administration of the suspension, illustrative

The system

Two devices, one documented processing cycle.

Rigenera N4SA processing unit
Rigeneracons RS single-use disaggregation device
Class IIaSingle use

Rigeneracons RS

Disaggregation device

Rigeneracons® RS: sterile, single-use Class IIa medical device, designed to mechanically disaggregate the auricular cartilage sample and collect the micrograft suspension through the calibrated 80 µm filter.

Class IReusable

Rigenera N4SA

Processing unit

Rigenera® N4SA: Class I motor-driven processing unit. The reusable unit provides the calibrated rotational impulse for the documented processing cycle.

Rigeneracons® RS: sterile, single-use Class IIa medical device. Rigenera® N4SA: Class I motor-driven processing unit. CE marked; accepted on the Great Britain market under current transitional arrangements. Registered with the MHRA.

Working with Actomed

Exclusive UK supply, structured onboarding.

Actomed is the exclusive UK supplier of Mytocel MSK, holding stock of Rigeneracons® RS and supporting N4SA installation.

Structured onboarding: protocol training, equipment orientation, first-case support and a documented consumables list.

KOOS and feedback templates for structured local outcome collection.

Clinic setupTraining and support
A gloved hand holding the round disaggregation grid of the single-use device.
The disaggregation grid of the single-use Rigeneracons RS device

Onboarding in five steps

  1. 01

    Professional discussion

    Clinical fit, evidence questions and clinic objectives.

  2. 02

    Pricing and configuration

    Reusable equipment, single-use devices and expected activity.

  3. 03

    Training and preparation

    Protocol training, equipment orientation, setup and supporting documentation.

  4. 04

    First-case pathway

    Agree practical first-case support and readiness before clinical use.

  5. 05

    Ongoing supply

    Consumables reordering, UK stock, product support and current resources.

Track record of the technology

450,000+5

procedures, manufacturer-reported, across dermatology, wound care, dentistry and orthopaedics

70+5

countries, manufacturer-reported, across dermatology, wound care, dentistry and orthopaedics

10+6

years in clinical use, manufacturer-reported, across dermatology, wound care, dentistry and orthopaedics

Manufacturer-reported: Rigenera® technology has been used in more than 450,000 procedures in over 70 countries across dermatology, wound care, dentistry and orthopaedics, and has been in clinical use for more than ten years across those fields.

References

  1. 1.Viganò M, Tessaro I, Trovato L, et al. Rationale and pre-clinical evidence for autologous cartilage micrografts in cartilage repair. 2018. View source
  2. 2.Marcarelli M, Zappia M, Rissolio L, et al. Cartilage micrografts as a novel non-invasive and non-arthroscopic autograft procedure for knee chondropathy: three-year follow-up. J Clin Med. 2021;10(2):322. View source
  3. 3.Tsoukas D, Muntean I, Simos C, Sabido-Vera R. Prospective observational study of a non-arthroscopic autologous cartilage micrografting technology for knee osteoarthritis. Bioengineering. 2023;10(11):1294. View source
  4. 4.Helito CP, Pessei V, Zaniboni C, Muntean I, et al. Efficacy of autologous micrografting technology in managing osteoarthritis pain: a pilot study. Bioengineering. 2024;11(11):1119. View source
  5. 5.Remedi (Regenera Activa). Mytocel MSK professional protocol. Manufacturer document. View source
  6. 6.Remedi. Mytocel MSK frequently asked questions. Manufacturer document. View source

Bring Mytocel MSK to your clinic.

UK stock, protocol training, first-case support and structured outcome collection, from the exclusive UK supplier.

Request UK pricingArrange an introduction